ClinicalTrials.gg
CompletedNCT02778399EDELWEISSUpdated Jul 21, 2022Results posted

A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis

A Phase 2 interventional study of Placebo and OBE2109 in Endometriosis, sponsored by ObsEva SA. Completed at 86 sites in 4 countries. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2022-07-21.

Sponsored by ObsEva SA · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
328
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing linzagolix in Endometriosis — none open to participants now, 1 under way, 1 of them phase 3. linzagolix · Endometriosis.

Started
2016
with 1 other
Phase 2
5 of 10
none open now
Registered
4th of 10
by date
Lead sponsor
1 of 10
ObsEva SA

Among the 10 studies testing linzagolix in Endometriosis, this one is one of 2 that started in 2016, is one of 5 in phase 2, and was the 4th registered.

Endometriosis

921 studies on the registry are indexed under Endometriosis; 267 are open to participants now.

Browse Endometriosis studies →

Open to participants now

None of the 10 studies testing linzagolix in Endometriosis is open now. The open studies under Endometriosis, anywhere →

About linzagolix

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 178 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 124 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing linzagolix in Endometriosis as a file.
02

Study summary

The primary objective of this study is to assess the efficacy and safety of a range of oral doses of OBE2109 versus placebo, in reducing endometriosis associated pain.

Read the detailed description

The study is a prospective, dose-finding, randomized, parallel group, double-blind, placebo-controlled phase 2b study investigating the efficacy and safety of OBE2109 in the treatment of 330 women with moderate-to-severe endometriosis associated pain.

Subject will be randomized to one of 6 treatment groups in a 1:1:1:1:1:1 ratio (1 placebo group, 5 dose groups with different dosage/regimen).

Eligible subjects will be offered the opportunity to continue treatment with OBE2109 in an extension phase. Subjects who do not continue in the extension will enter the treatment-free follow-up phase of the study.

03

Conditions studied

  • Endometriosis

Keywords

  • Pelvic Pain
  • Endometriosis
  • Dysmenorrhea
  • Dyspareunia
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • The subject must have had her most recent surgical and - if available - histological, diagnosis of pelvic endometriosis up to 10 years before screening.
  • The subject has moderate to severe endometriosis-associated pain during the screening period.
  • The subject has regular menstrual cycles.
  • The subject has a ≥ 18 kg/m2 at the screening visit.

Key Exclusion Criteria:

  • The subject is pregnant or breast feeding or is planning a pregnancy within the duration of the treatment period of the study.
  • The subject had an interventional surgery for endometriosis performed within a period of 60 days before screening.
  • The subject did not respond to prior treatment with gonadotropin releasing hormone (GnRH) agonists or GnRH antagonists for endometriosis.
  • The subject has a history of, or known osteoporosis or other metabolic bone disease.
  • The subject has chronic pelvic pain that is not caused by endometriosis and requires chronic analgesic / therapy, or that would interfere with the assessment of endometriosis related pain.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
328 participants (actual)

Study arms

  • Experimental
    OBE2109 50 mg

    Drug: OBE2109

  • Experimental
    OBE2109 75mg fixed dose (FD)

    Drug: OBE2109

  • Experimental
    OBE2109 75mg titrated dose (TD)

    Drug: OBE2109

  • Experimental
    OBE2109 100mg

    Drug: OBE2109

  • Experimental
    OBE2109 200 mg

    Drug: OBE2109

  • Placebo comparator
    Placebo / OBE2109 100mg

    Participants received placebo for the first 12 weeks and were then crossed-over to active treatment with OBE2109 100mg for a further 12 weeks.

    Drug: Placebo · Drug: OBE2109

Interventions

  • DrugPlacebo

    Placebo tablets for oral administration once daily

  • OBE2109 tablets for oral administration once daily

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects With 30% or Greater Reduction From Baseline to Week 12 in Mean Overall Pelvic Pain Score (0-3 VRS)

    The primary efficacy endpoint of the study was a response at Week 12, with response defined as a reduction of 30% or greater from baseline in the mean overall pelvic pain score, defined as the mean of daily pain scores reported in electronic diary during the preceding 28 days (4-week period), assessed on a Verbal Rating Scale for pelvic pain of 0 (no pain) to 3 (severe pain). The baseline mean score was calculated as the mean of daily scores recorded in electronic diary over the two complete menstrual cycles performed during the screening period. The relevant time points are Baseline and Week 12.

    Time frame: From baseline to week 12

Secondary outcomes

  1. Change From Baseline to Week 12 in the Mean Overall Pelvic Pain Score (0-10 NRS)

    This endpoint corresponds to the change from baseline to Week 12 in the mean overall pelvic pain score, defined as the mean of daily pain scores reported in electronic diary during the preceding 28 days (4-week period), assessed on a Numerical Rating Scale (NRS) for pelvic pain of 0 (no pelvic pain) to 10 (worst pelvic pain imaginable). The baseline mean score was calculated as the mean of daily scores recorded in electronic diary over the two complete menstrual cycles performed during the screening period. The relevant time points are Baseline and Week 12.

    Time frame: From baseline to week 12

  2. Percentage of Subjects With 30% or Greater Reduction From Baseline to Week 12 in Mean Pelvic Pain Scores (0-3 VRS) for Days With Uterine Bleeding

    This endpoint corresponds to a response at Week 12, with response defined as a reduction of 30% or greater from baseline in the mean pelvic pain score for days with uterine bleeding/spotting, defined as the mean of daily pain scores on days with uterine bleeding/spotting recorded in electronic diary during the preceding 28 days (4-week period), assessed on a Verbal Rating Scale for pelvic pain of 0 (no pain) to 3 (severe pain). The baseline mean score was calculated as the mean of daily scores recorded in electronic diary over the two complete menstrual cycles performed during the screening period. The relevant time points are Baseline and Week 12.

    Time frame: From baseline to week 12

  3. Percentage of Subjects With 30% or Greater Reduction From Baseline to Week 12 in Mean Pelvic Pain Scores (0-3 VRS) for Days With no Uterine Bleeding

    This endpoint corresponds to a response at Week 12, with response defined as a reduction of 30% or greater from baseline in the mean pelvic pain score for days with no uterine bleeding, defined as the mean of daily pain scores on days with no uterine bleeding recorded in electronic diary during the preceding 28 days (4-week period) on a Verbal Rating Scale for pelvic pain of 0 (no pain) to 3 (severe pain). The baseline mean score was calculated as the mean of daily scores recorded in electronic diary over the two complete menstrual cycles performed during the screening period. The relevant time points are Baseline and Week 12.

    Time frame: From baseline to week 12

  4. Change From Baseline to Week 12 in the Mean Dyspareunia Score (0-3 VRS)

    This endpoint corresponds to the change from baseline to Week 12 in the mean dyspareunia score, defined as the mean of daily dyspareunia scores recorded in electronic diary during the preceding 28 days (4-week period), assessed on a 0-3 Verbal Rating Scale (VRS) for dyspareunia, with 0 representing "No discomfort during sexual intercourse" and 3 representing "I avoided sexual intercourse because of pain". The baseline mean score was calculated as the mean of daily scores recorded in electronic diary over the two complete menstrual cycles performed during the screening period. The dyspareunia questionnaire also included an option "not applicable: I was not sexually active for reasons other than my endometriosis or did not have sexual intercourse"; for scoring, answering "not applicable" was considered like a missing value. The relevant time points are Baseline and Week 12.

    Time frame: From baseline to week 12

  5. Change From Baseline to Week 12 in the Mean Dyschezia Score (0-10 NRS)

    This endpoint corresponds to the change from baseline to week 12 in the mean dyschezia score, defined as the mean of weekly dyschezia scores reported in electronic diary during the preceding 28 days (4-week period), assessed on a 0-10 Numerical Rating Scale for dyschezia, with 0 representing no pain and 10 representing the worst pain imaginable. The baseline mean score was calculated as the mean of weekly scores recorded in electronic diary over the two complete menstrual cycles performed during the screening period. The relevant time points are Baseline and Week 12.

    Time frame: From baseline to week 12

  6. Percentage of Subjects With Any Analgesics Use at Week 12

    This endpoint corresponds to the percentage of subjects at week 12 who recorded at least one pain medication intake in electronic diary during the preceding 28 days (4-week period).

    Time frame: Up to week 12

  7. Change From Baseline to Week 12 in the Mean Score of Endometriosis Health Profile-30 (EHP-30) Pain Domain

    This endpoint corresponds to the change from baseline to Week 12 in the mean score of pain dimension of the EHP-30. The EHP-30 questionnaire was answered on electronic diary after activation by site staff during subject's monthly visits at site. The EHP-30 pain dimension consists of 11 items each addressing the effect of pain on various activities in the past 4 weeks and each assessed on a 5-point scale (0=Never through to 4=Always). Scaled score was equalled to total of raw score of each item in scale divided by the maximum possible raw score of all the items in the dimension, multiplied by 100, resulting in a score on a scale from 0 (best possible health status) to 100 (worst possible health status). The relevant time points are Baseline and Week 12.

    Time frame: From baseline to week 12

  8. Percentage of Subjects With Improvement in the Patient Global Impression of Change (PGIC) Score at Week 12

    The PGIC questionnaire consists of one question rated on a seven point scale (1="Very Much Improved" to 7="Very Much Worse"), with which the subject had to qualify her overall status since the start of the study. The PGIC was answered on electronic diary after activation by site staff during Week 12 visit at site. This endpoint corresponds to the percentage of subjects with an "improvement" in the PGIC score, which includes all subjects who answered "Very much improved" or "Much improved" or "Minimally improved" at Week 12.

    Time frame: Up to week 12

  9. Percentage of Subjects With an Endometriosis Severity Score of "Severe" at Week 12

    Subject was asked monthly on electronic diary to assess their impression of endometriosis severity, considering the preceding 4-weeks, with following possible answers: no symptoms, very mild, mild, moderate, severe. This question was programmed to raise automatically every 4 weeks on the subject electronic diary. Result reported here is the percentage of subjects who answered "severe" at week 12.

    Time frame: Up to week 12

  10. Change From Baseline to Week 12 in the Difficulty in Doing Daily Activities Mean Score

    This endpoint corresponds to the change from baseline to Week 12 in the mean of daily scores for "difficulty in doing daily activities", assessed via electronic diary during the preceding 28 days (4-week period), on a Numerical Rating Scale (NRS) of 0 (no difficulty doing daily activities) to 10 (unable to do daily activities). The baseline mean score was calculated as the mean of daily scores recorded in electronic diary over the two complete menstrual cycles performed during the screening period. The relevant time points are Baseline and Week 12.

    Time frame: From baseline to week 12

  11. Percentage Change From Baseline to Week 24 in Bone Mineral Density (BMD)

    Change from baseline to Week 24 in BMD assessed by dual-energy X-ray absorptiometry (DXA) scan of LUMBAR SPINE.

    Time frame: From baseline up to week 24

  12. Number of Non Benign Endometrial Biopsies at Week 24

    Any pathological changes in the endometrium at week 24 were assessed from endometrial biopsies. The number of non benign biopsies at Week 24 is presented per treatment arm. Note: an isolated case of hyperplasia (without atypia) was observed at week 12 in the 200 mg group in a subject whose screening biopsy results were normal. A follow-up biopsy at week 24 revealed no abnormalities.

    Time frame: Week 24

  13. Change From Baseline to Week 24 in Endometrial Thickness Measured by Transvaginal Ultrasound (TVUS)

    The endometrium thickness was measured by TVUS at screening and at Week 24 visit by the gynaecologist and result was recorded in mm. This endpoint reports the changes from baseline to Week 24 in the endometrial thickness.

    Time frame: From baseline up to week 24

  14. Percentage Change From Baseline to Week 24 in the Clinical Laboratory Assessments: LDL

    This endpoint reports the change from baseline up to Week 24 in the clinical laboratory assessments: LDL cholesterol.

    Time frame: From baseline up to week 24

  15. Percentage Change From Baseline to Week 24 in Clinical Laboratory Assessments: HDL

    This endpoint reports the change from baseline to week 24 in clinical laboratory assessments: HDL cholesterol.

    Time frame: From Baseline up to week 24

  16. Percentage Change From Baseline to Week 24 in Clinical Laboratory Assessments: Triglycerides

    This endpoint reports the change from baseline to week 24 in clinical laboratory assessments: triglycerides.

    Time frame: From baseline up to week 24

07

Results

Posted Jul 21, 2022

Participant flow

A total of 328 females were randomized at 62 sites in 4 countries: 48 sites in USA (177 subjects), 5 sites in Poland (67 subjects), 5 sites in Ukraine (73 subjects) and 4 sites in Russia (11 subjects).

Up to Week 12 Treatment Period
Participant flow — Up to Week 12 Treatment Period
MilestonePlacebo / OBE2109 100mgOBE2109 50mgOBE2109 75mg FDOBE2109 75mg TDOBE2109 100mgOBE2109 200mg
Started544957585357
Included in safety set544957585257
Included in fas534956585156
Completed454553514549
Not completed944788
Withdrew: Adverse event123233
Withdrew: Withdrawal by subject521423
Withdrew: Protocol violation000010
Withdrew: Lost to follow-up300002
Withdrew: Other - reason not stated000120
Week 12 to Week 24 Treatment Period
Participant flow — Week 12 to Week 24 Treatment Period
MilestonePlacebo / OBE2109 100mgOBE2109 50mgOBE2109 75mg FDOBE2109 75mg TDOBE2109 100mgOBE2109 200mg
Started454553514549
Completed374148463942
Not completed845567
Withdrew: Adverse event202132
Withdrew: Withdrawal by subject320322
Withdrew: Protocol violation010000
Withdrew: Lost to follow-up210102
Withdrew: Pregnancy102000
Withdrew: Other - reason not stated001011

Outcome measures

PrimaryPercentage of Subjects With 30% or Greater Reduction From Baseline to Week 12 in Mean Overall Pelvic Pain Score (0-3 VRS)

The primary efficacy endpoint of the study was a response at Week 12, with response defined as a reduction of 30% or greater from baseline in the mean overall pelvic pain score, defined as the mean of daily pain scores reported in electronic diary during the preceding 28 days (4-week period), assessed on a Verbal Rating Scale for pelvic pain of 0 (no pain) to 3 (severe pain). The baseline mean score was calculated as the mean of daily scores recorded in electronic diary over the two complete menstrual cycles performed during the screening period. The relevant time points are Baseline and Week 12.

Time frame:
From baseline to week 12
Reported as:
Number · percentage of subjects
Percentage of Subjects With 30% or Greater Reduction From Baseline to Week 12 in Mean Overall Pelvic Pain Score (0-3 VRS)
percentage of subjectsPlacebo / OBE2109 100mgOBE2109 50mgOBE2109 75mg FD + TDOBE2109 100mgOBE2109 200mg
Percentage of Subjects With 30% or Greater Reduction From Baseline to Week 12 in Mean Overall Pelvic Pain Score (0-3 VRS)34.549.461.556.456.3
SecondaryChange From Baseline to Week 12 in the Mean Overall Pelvic Pain Score (0-10 NRS)

This endpoint corresponds to the change from baseline to Week 12 in the mean overall pelvic pain score, defined as the mean of daily pain scores reported in electronic diary during the preceding 28 days (4-week period), assessed on a Numerical Rating Scale (NRS) for pelvic pain of 0 (no pelvic pain) to 10 (worst pelvic pain imaginable). The baseline mean score was calculated as the mean of daily scores recorded in electronic diary over the two complete menstrual cycles performed during the screening period. The relevant time points are Baseline and Week 12.

Time frame:
From baseline to week 12
Reported as:
Mean · score on a scale
Change From Baseline to Week 12 in the Mean Overall Pelvic Pain Score (0-10 NRS)
score on a scalePlacebo / OBE2109 100mgOBE2109 50mgOBE2109 75mg FD + TDOBE2109 100mgOBE2109 200mg
Change From Baseline to Week 12 in the Mean Overall Pelvic Pain Score (0-10 NRS)-1.17 (-1.70 to -0.65)-1.75 (-2.29 to -1.20)-2.15 (-2.50 to -1.80)-2.06 (-2.60 to -1.52)-2.14 (-2.65 to -1.63)
SecondaryPercentage of Subjects With 30% or Greater Reduction From Baseline to Week 12 in Mean Pelvic Pain Scores (0-3 VRS) for Days With Uterine Bleeding

This endpoint corresponds to a response at Week 12, with response defined as a reduction of 30% or greater from baseline in the mean pelvic pain score for days with uterine bleeding/spotting, defined as the mean of daily pain scores on days with uterine bleeding/spotting recorded in electronic diary during the preceding 28 days (4-week period), assessed on a Verbal Rating Scale for pelvic pain of 0 (no pain) to 3 (severe pain). The baseline mean score was calculated as the mean of daily scores recorded in electronic diary over the two complete menstrual cycles performed during the screening period. The relevant time points are Baseline and Week 12.

Time frame:
From baseline to week 12
Reported as:
Number · percentage of subjects
Percentage of Subjects With 30% or Greater Reduction From Baseline to Week 12 in Mean Pelvic Pain Scores (0-3 VRS) for Days With Uterine Bleeding
percentage of subjectsPlacebo / OBE2109 100mgOBE2109 50mgOBE2109 75mg FD + TDOBE2109 100mgOBE2109 200mg
Percentage of Subjects With 30% or Greater Reduction From Baseline to Week 12 in Mean Pelvic Pain Scores (0-3 VRS) for Days With Uterine Bleeding28.543.368.268.678.9
SecondaryPercentage of Subjects With 30% or Greater Reduction From Baseline to Week 12 in Mean Pelvic Pain Scores (0-3 VRS) for Days With no Uterine Bleeding

This endpoint corresponds to a response at Week 12, with response defined as a reduction of 30% or greater from baseline in the mean pelvic pain score for days with no uterine bleeding, defined as the mean of daily pain scores on days with no uterine bleeding recorded in electronic diary during the preceding 28 days (4-week period) on a Verbal Rating Scale for pelvic pain of 0 (no pain) to 3 (severe pain). The baseline mean score was calculated as the mean of daily scores recorded in electronic diary over the two complete menstrual cycles performed during the screening period. The relevant time points are Baseline and Week 12.

Time frame:
From baseline to week 12
Reported as:
Number · percentage of subjects
Percentage of Subjects With 30% or Greater Reduction From Baseline to Week 12 in Mean Pelvic Pain Scores (0-3 VRS) for Days With no Uterine Bleeding
percentage of subjectsPlacebo / OBE2109 100mgOBE2109 50mgOBE2109 75mg FD + TDOBE2109 100mgOBE2109 200mg
Percentage of Subjects With 30% or Greater Reduction From Baseline to Week 12 in Mean Pelvic Pain Scores (0-3 VRS) for Days With no Uterine Bleeding37.146.258.561.547.7
SecondaryChange From Baseline to Week 12 in the Mean Dyspareunia Score (0-3 VRS)

This endpoint corresponds to the change from baseline to Week 12 in the mean dyspareunia score, defined as the mean of daily dyspareunia scores recorded in electronic diary during the preceding 28 days (4-week period), assessed on a 0-3 Verbal Rating Scale (VRS) for dyspareunia, with 0 representing "No discomfort during sexual intercourse" and 3 representing "I avoided sexual intercourse because of pain". The baseline mean score was calculated as the mean of daily scores recorded in electronic diary over the two complete menstrual cycles performed during the screening period. The dyspareunia questionnaire also included an option "not applicable: I was not sexually active for reasons other than my endometriosis or did not have sexual intercourse"; for scoring, answering "not applicable" was considered like a missing value. The relevant time points are Baseline and Week 12.

Time frame:
From baseline to week 12
Reported as:
Mean · score on a scale
Change From Baseline to Week 12 in the Mean Dyspareunia Score (0-3 VRS)
score on a scalePlacebo / OBE2109 100mgOBE2109 50mgOBE2109 75mg FD + TDOBE2109 100mgOBE2109 200mg
Change From Baseline to Week 12 in the Mean Dyspareunia Score (0-3 VRS)-0.39 (-0.63 to -0.16)-0.62 (-0.87 to -0.37)-0.59 (-0.76 to -0.43)-0.66 (-0.91 to -0.41)-0.79 (-1.03 to -0.54)
SecondaryChange From Baseline to Week 12 in the Mean Dyschezia Score (0-10 NRS)

This endpoint corresponds to the change from baseline to week 12 in the mean dyschezia score, defined as the mean of weekly dyschezia scores reported in electronic diary during the preceding 28 days (4-week period), assessed on a 0-10 Numerical Rating Scale for dyschezia, with 0 representing no pain and 10 representing the worst pain imaginable. The baseline mean score was calculated as the mean of weekly scores recorded in electronic diary over the two complete menstrual cycles performed during the screening period. The relevant time points are Baseline and Week 12.

Time frame:
From baseline to week 12
Reported as:
Mean · score on a scale/week
Change From Baseline to Week 12 in the Mean Dyschezia Score (0-10 NRS)
score on a scale/weekPlacebo / OBE2109 100mgOBE2109 50mgOBE2109 75mg FD + TDOBE2109 100mgOBE2109 200mg
Change From Baseline to Week 12 in the Mean Dyschezia Score (0-10 NRS)-0.78 (-1.34 to -0.22)-1.55 (-2.14 to -0.96)-1.87 (-2.25 to -1.49)-1.97 (-2.55 to -1.39)-1.7 (-2.25 to -1.15)
SecondaryPercentage of Subjects With Any Analgesics Use at Week 12

This endpoint corresponds to the percentage of subjects at week 12 who recorded at least one pain medication intake in electronic diary during the preceding 28 days (4-week period).

Time frame:
Up to week 12
Reported as:
Number · percentage of subjects
Percentage of Subjects With Any Analgesics Use at Week 12
percentage of subjectsPlacebo / OBE2109 100mgOBE2109 50mgOBE2109 75mg FD + TDOBE2109 100mgOBE2109 200mg
Percentage of Subjects With Any Analgesics Use at Week 1290.6 (78.6 to 96.2)77.1 (62.7 to 87.1)74.8 (65.7 to 82.1)68.8 (54.1 to 80.5)72.1 (58.4 to 82.7)
SecondaryChange From Baseline to Week 12 in the Mean Score of Endometriosis Health Profile-30 (EHP-30) Pain Domain

This endpoint corresponds to the change from baseline to Week 12 in the mean score of pain dimension of the EHP-30. The EHP-30 questionnaire was answered on electronic diary after activation by site staff during subject's monthly visits at site. The EHP-30 pain dimension consists of 11 items each addressing the effect of pain on various activities in the past 4 weeks and each assessed on a 5-point scale (0=Never through to 4=Always). Scaled score was equalled to total of raw score of each item in scale divided by the maximum possible raw score of all the items in the dimension, multiplied by 100, resulting in a score on a scale from 0 (best possible health status) to 100 (worst possible health status). The relevant time points are Baseline and Week 12.

Time frame:
From baseline to week 12
Reported as:
Mean · score on a scale
Change From Baseline to Week 12 in the Mean Score of Endometriosis Health Profile-30 (EHP-30) Pain Domain
score on a scalePlacebo / OBE2109 100mgOBE2109 50mgOBE2109 75mg FD + TDOBE2109 100mgOBE2109 200mg
Change From Baseline to Week 12 in the Mean Score of Endometriosis Health Profile-30 (EHP-30) Pain Domain-7.4 (-12.36 to -2.41)-18.5 (-23.44 to -13.47)-18.9 (-22.20 to -15.69)-19.4 (-24.28 to -14.55)-20.9 (-25.69 to -16.10)
SecondaryPercentage of Subjects With Improvement in the Patient Global Impression of Change (PGIC) Score at Week 12

The PGIC questionnaire consists of one question rated on a seven point scale (1="Very Much Improved" to 7="Very Much Worse"), with which the subject had to qualify her overall status since the start of the study. The PGIC was answered on electronic diary after activation by site staff during Week 12 visit at site. This endpoint corresponds to the percentage of subjects with an "improvement" in the PGIC score, which includes all subjects who answered "Very much improved" or "Much improved" or "Minimally improved" at Week 12.

Time frame:
Up to week 12
Reported as:
Number · percentage of subjects
Percentage of Subjects With Improvement in the Patient Global Impression of Change (PGIC) Score at Week 12
percentage of subjectsPlacebo / OBE2109 100mgOBE2109 50mgOBE2109 75mg FD + TDOBE2109 100mgOBE2109 200mg
Percentage of Subjects With Improvement in the Patient Global Impression of Change (PGIC) Score at Week 1265.178.680.68695.7
SecondaryPercentage of Subjects With an Endometriosis Severity Score of "Severe" at Week 12

Subject was asked monthly on electronic diary to assess their impression of endometriosis severity, considering the preceding 4-weeks, with following possible answers: no symptoms, very mild, mild, moderate, severe. This question was programmed to raise automatically every 4 weeks on the subject electronic diary. Result reported here is the percentage of subjects who answered "severe" at week 12.

Time frame:
Up to week 12
Reported as:
Number · percentage of subjects
Percentage of Subjects With an Endometriosis Severity Score of "Severe" at Week 12
percentage of subjectsPlacebo / OBE2109 100mgOBE2109 50mgOBE2109 75mg FD + TDOBE2109 100mgOBE2109 200mg
Percentage of Subjects With an Endometriosis Severity Score of "Severe" at Week 1220.94.57.84.54.2
SecondaryChange From Baseline to Week 12 in the Difficulty in Doing Daily Activities Mean Score

This endpoint corresponds to the change from baseline to Week 12 in the mean of daily scores for "difficulty in doing daily activities", assessed via electronic diary during the preceding 28 days (4-week period), on a Numerical Rating Scale (NRS) of 0 (no difficulty doing daily activities) to 10 (unable to do daily activities). The baseline mean score was calculated as the mean of daily scores recorded in electronic diary over the two complete menstrual cycles performed during the screening period. The relevant time points are Baseline and Week 12.

Time frame:
From baseline to week 12
Reported as:
Mean · score on a scale
Change From Baseline to Week 12 in the Difficulty in Doing Daily Activities Mean Score
score on a scalePlacebo / OBE2109 100mgOBE2109 50mgOBE2109 75mg FD + TDOBE2109 100mgOBE2109 200mg
Change From Baseline to Week 12 in the Difficulty in Doing Daily Activities Mean Score-1.17 (-1.68 to -0.65)-1.65 (-2.18 to -1.12)-2.06 (-2.41 to -1.72)-1.88 (-2.41 to -1.36)-1.99 (-2.49 to -1.49)
SecondaryPercentage Change From Baseline to Week 24 in Bone Mineral Density (BMD)

Change from baseline to Week 24 in BMD assessed by dual-energy X-ray absorptiometry (DXA) scan of LUMBAR SPINE.

Time frame:
From baseline up to week 24
Reported as:
Mean · percentage change
Percentage Change From Baseline to Week 24 in Bone Mineral Density (BMD)
percentage changePlacebo / OBE2109 100mgOBE2109 50mgOBE2109 75mg FDOBE2109 75mg TDOBE2109 100mgOBE2109 200mg
Percentage Change From Baseline to Week 24 in Bone Mineral Density (BMD)-0.929 (-1.71 to -0.15)0.137 (-0.83 to 1.11)-0.798 (-1.57 to -0.03)-1.000 (-1.71 to -0.29)-1.365 (-2.14 to -0.59)-2.602 (-3.56 to -1.65)
SecondaryNumber of Non Benign Endometrial Biopsies at Week 24

Any pathological changes in the endometrium at week 24 were assessed from endometrial biopsies. The number of non benign biopsies at Week 24 is presented per treatment arm. Note: an isolated case of hyperplasia (without atypia) was observed at week 12 in the 200 mg group in a subject whose screening biopsy results were normal. A follow-up biopsy at week 24 revealed no abnormalities.

Time frame:
Week 24
Reported as:
Number · Non benign biopsies
Number of Non Benign Endometrial Biopsies at Week 24
Non benign biopsiesPlacebo / OBE2109 100mgOBE2109 50mgOBE2109 75mg FDOBE2109 75mg TDOBE2109 100mgOBE2109 200mg
Number of Non Benign Endometrial Biopsies at Week 24000000
SecondaryChange From Baseline to Week 24 in Endometrial Thickness Measured by Transvaginal Ultrasound (TVUS)

The endometrium thickness was measured by TVUS at screening and at Week 24 visit by the gynaecologist and result was recorded in mm. This endpoint reports the changes from baseline to Week 24 in the endometrial thickness.

Time frame:
From baseline up to week 24
Reported as:
Mean · mm
Change From Baseline to Week 24 in Endometrial Thickness Measured by Transvaginal Ultrasound (TVUS)
mmPlacebo / OBE2109 100mgOBE2109 50mgOBE2109 75mg FDOBE2109 75mg TDOBE2109 100mgOBE2109 200mg
Change From Baseline to Week 24 in Endometrial Thickness Measured by Transvaginal Ultrasound (TVUS)-3.1 ± 4.64-1.5 ± 4.28-2.3 ± 4.15-1.3 ± 3.70-1.6 ± 4.56-4.0 ± 3.39
SecondaryPercentage Change From Baseline to Week 24 in the Clinical Laboratory Assessments: LDL

This endpoint reports the change from baseline up to Week 24 in the clinical laboratory assessments: LDL cholesterol.

Time frame:
From baseline up to week 24
Reported as:
Mean · percent change
Percentage Change From Baseline to Week 24 in the Clinical Laboratory Assessments: LDL
percent changePlacebo / OBE2109 100mgOBE2109 50mgOBE2109 75mg FDOBE2109 75mg TDOBE2109 100mgOBE2109 200mg
Percentage Change From Baseline to Week 24 in the Clinical Laboratory Assessments: LDL1.7 ± 15.7-0.3 ± 16.67.4 ± 55.27.3 ± 21.49.7 ± 20.710.3 ± 21.7
SecondaryPercentage Change From Baseline to Week 24 in Clinical Laboratory Assessments: HDL

This endpoint reports the change from baseline to week 24 in clinical laboratory assessments: HDL cholesterol.

Time frame:
From Baseline up to week 24
Reported as:
Mean · percent change
Percentage Change From Baseline to Week 24 in Clinical Laboratory Assessments: HDL
percent changePlacebo / OBE2109 100mgOBE2109 50mgOBE2109 75mg FDOBE2109 75mg TDOBE2109 100mgOBE2109 200mg
Percentage Change From Baseline to Week 24 in Clinical Laboratory Assessments: HDL5.5 ± 11.72.9 ± 12.93.8 ± 17.86.2 ± 24.15.6 ± 18.08.1 ± 14.7
SecondaryPercentage Change From Baseline to Week 24 in Clinical Laboratory Assessments: Triglycerides

This endpoint reports the change from baseline to week 24 in clinical laboratory assessments: triglycerides.

Time frame:
From baseline up to week 24
Reported as:
Mean · percent change
Percentage Change From Baseline to Week 24 in Clinical Laboratory Assessments: Triglycerides
percent changePlacebo / OBE2109 100mgOBE2109 50mgOBE2109 75mg FDOBE2109 75mg TDOBE2109 100mgOBE2109 200mg
Percentage Change From Baseline to Week 24 in Clinical Laboratory Assessments: Triglycerides17.9 ± 38.616.4 ± 41.35.2 ± 35.213.6 ± 45.020.5 ± 80.624.0 ± 57.7

Adverse events

Collected over From baseline up to week 24. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo BL-Wk120/55 (0%)1/55 (1.8%)22/55 (40%)
OBE2109 100mg Wk12-Wk240/55 (0%)0/55 (0%)19/55 (34.5%)
OBE2109 50mg BL-Wk240/49 (0%)1/49 (2%)27/49 (55.1%)
OBE2109 75mg FD BL-Wk240/58 (0%)0/58 (0%)30/58 (51.7%)
OBE2109 75mg TD BL-Wk240/56 (0%)0/56 (0%)36/56 (64.3%)
OBE2109 100mg BL-Wk240/52 (0%)3/52 (5.8%)31/52 (59.6%)
OBE2109 200mg BL-Wk240/57 (0%)1/57 (1.8%)39/57 (68.4%)
Most frequent serious events
Most frequent serious events
EventPlacebo BL-Wk12OBE2109 100mg Wk12-Wk24OBE2109 50mg BL-Wk24OBE2109 75mg FD BL-Wk24OBE2109 75mg TD BL-Wk24OBE2109 100mg BL-Wk24OBE2109 200mg BL-Wk24
Pyelonephritis acuteInfections and infestations0/550/551/490/580/560/520/57
Ectopic pregnancyPregnancy, puerperium and perinatal conditions0/550/550/490/580/561/520/57
EnterocolitisGastrointestinal disorders0/550/550/490/580/561/520/57
MetrorrhagiaReproductive system and breast disorders0/550/550/490/580/561/520/57
Stab woundInjury, poisoning and procedural complications1/550/550/490/580/560/520/57
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders0/550/550/490/580/560/521/57
Most frequent other events
Showing 10 of 20
Most frequent other events
EventPlacebo BL-Wk12OBE2109 100mg Wk12-Wk24OBE2109 50mg BL-Wk24OBE2109 75mg FD BL-Wk24OBE2109 75mg TD BL-Wk24OBE2109 100mg BL-Wk24OBE2109 200mg BL-Wk24
hot flushVascular disorders6/555/559/4911/5813/5615/5226/57
headacheNervous system disorders14/559/5512/4910/5816/5615/5217/57
nasopharyngitisInfections and infestations3/551/558/497/584/562/521/57
arthralgiaMusculoskeletal and connective tissue disorders0/550/551/490/581/563/529/57
nauseaGastrointestinal disorders1/550/553/492/582/564/527/57
mood swingsPsychiatric disorders5/551/552/491/583/563/522/57
blood creatine phosphokinase increasedInvestigations1/551/551/494/585/562/524/57
urinary tract infectionInfections and infestations0/550/551/493/583/562/525/57
abdominal pain upperGastrointestinal disorders1/552/551/490/581/564/521/57
fatigueGeneral disorders0/550/551/490/580/564/522/57

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Placebo / OBE2109 100mgOBE2109 50mgOBE2109 75mg FDOBE2109 75mg TDOBE2109 100mgOBE2109 200mgTotal
<=18 years0000000
Between 18 and 65 years534956585156323
>=65 years0000000
Age, Continuous
Age, Continuous(years)Placebo / OBE2109 100mgOBE2109 50mgOBE2109 75mg FDOBE2109 75mg TDOBE2109 100mgOBE2109 200mgTotal
Mean32.4 ± 5.7830.9 ± 5.9832.0 ± 6.8331.2 ± 5.8533.0 ± 5.7830.9 ± 6.0331.7 ± 6.06
Sex: Female, Male
Sex: Female, Male(Participants)Placebo / OBE2109 100mgOBE2109 50mgOBE2109 75mg FDOBE2109 75mg TDOBE2109 100mgOBE2109 200mgTotal
Female534956585156323
Male0000000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo / OBE2109 100mgOBE2109 50mgOBE2109 75mg FDOBE2109 75mg TDOBE2109 100mgOBE2109 200mgTotal
Hispanic or Latino35374527
Not Hispanic or Latino251827252423142
Unknown or Not Reported252626262328154
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo / OBE2109 100mgOBE2109 50mgOBE2109 75mg FDOBE2109 75mg TDOBE2109 100mgOBE2109 200mgTotal
American Indian or Alaska Native0000000
Asian0000000
Native Hawaiian or Other Pacific Islander0000000
Black or African American42583325
White494650504652293
More than one race0110215
Unknown or Not Reported0000000
08

Study locations

86 sites
  • Site reference ID 455
    Chandler, Arizona, United States
  • Site reference ID 439
    Scottsdale, Arizona, United States
  • Site reference ID 462
    Arcadia, California, United States
  • Site reference ID 405
    Chino, California, United States
  • Site reference ID 463
    Huntington Park, California, United States
  • Site refenrec ID 469
    Northridge, California, United States
  • Site reference ID 431
    San Diego, California, United States
  • Site reference ID 440
    Tustin, California, United States
  • Site reference ID 474
    Denver, Colorado, United States
  • Site reference ID 450
    Lakewood, Colorado, United States
  • Site reference ID 425
    Longmont, Colorado, United States
  • Site reference ID 410
    Washington, District of Columbia, United States
  • Site reference ID 457
    Boca Raton, Florida, United States
  • Site reference ID 418
    Clearwater, Florida, United States
  • Site reference ID 437
    Gainesville, Florida, United States
  • Site reference ID 458
    Jensen Beach, Florida, United States
  • Site reference ID 420
    Miami Lakes, Florida, United States
  • Site reference ID 441
    Miami Springs, Florida, United States
  • Site reference ID 411
    Miami, Florida, United States
  • Site reference ID 424
    Miami, Florida, United States
  • Site reference ID 435
    Miami, Florida, United States
  • Site reference ID 423
    New Port Richey, Florida, United States
  • Site reference ID 426
    Tampa, Florida, United States
  • Site reference ID 442
    Wellington, Florida, United States
  • Site reference ID 428
    Atlanta, Georgia, United States
  • Site reference ID 459
    Atlanta, Georgia, United States
  • Site reference ID 475
    Nampa, Idaho, United States
  • Site reference ID 465
    Oak Brook, Illinois, United States
  • Site reference ID 404
    Shawnee Mission, Kansas, United States
  • Site reference ID 456
    Wichita, Kansas, United States
  • Site reference ID 454
    Marrero, Louisiana, United States
  • Site reference ID 453
    Metairie, Louisiana, United States
  • Site reference ID 478
    Glen Burnie, Maryland, United States
  • Site reference ID 445
    Fall River, Massachusetts, United States
  • Site reference ID 471
    Fall River, Massachusetts, United States
  • Site reference ID 430
    Ann Arbor, Michigan, United States
  • Site reference ID 409
    Bay City, Michigan, United States
  • Site reference ID 468
    Saginaw, Michigan, United States
  • Site reference ID 473
    Saginaw, Michigan, United States
  • Site reference ID 427
    Southfield, Michigan, United States
  • Site reference ID 421
    Albuquerque, New Mexico, United States
  • Site reference ID 466
    New York, New York, United States
  • Site reference ID 436
    Greensboro, North Carolina, United States
  • Site reference ID 433
    Morehead City, North Carolina, United States
  • Site reference ID 443
    Dayton, Ohio, United States
  • Site reference ID 472
    Franklin, Ohio, United States
  • Site reference ID 415
    Tiffin, Ohio, United States
  • Site reference ID 414
    Westerville, Ohio, United States
  • Site reference ID 419
    Bryn Mawr, Pennsylvania, United States
  • Site reference ID 449
    Jenkintown, Pennsylvania, United States
  • Site reference ID 476
    Columbia, South Carolina, United States
  • Site reference ID 408
    Bristol, Tennessee, United States
  • Site reference ID 403
    Chattanooga, Tennessee, United States
  • Site reference ID 429
    Nashville, Tennessee, United States
  • Site reference ID 452
    Austin, Texas, United States
  • Site reference ID 461
    Beaumont, Texas, United States
  • Site reference ID 447
    Dallas, Texas, United States
  • Site reference ID 460
    Dallas, Texas, United States
  • Site reference ID 464
    Fort Worth, Texas, United States
  • Site reference ID 413
    Houston, Texas, United States
  • Site reference ID 434
    Houston, Texas, United States
  • Site reference ID 479
    Houston, Texas, United States
  • Site reference ID 451
    San Antonio, Texas, United States
  • Site reference ID 402
    Schertz, Texas, United States
  • Site reference ID 432
    Webster, Texas, United States
  • Site reference ID 422
    Draper, Utah, United States
  • Site reference ID 467
    Centreville, Virginia, United States
  • Site reference ID 407
    Norfolk, Virginia, United States
  • Site reference ID 412
    Richmond, Virginia, United States
  • Site reference ID 417
    Richmond, Virginia, United States
  • Site reference ID 406
    Seattle, Washington, United States
  • Site reference ID 101
    Katowice, Poland
  • Site reference ID 102
    Katowice, Poland
  • Site reference ID 104
    Lublin, Poland
  • Site reference ID 105
    Lublin, Poland
  • Site reference ID 103
    Szczecin, Poland
  • Site reference ID 201
    Moscow, Russian Federation
  • Site reference ID 202
    Moscow, Russian Federation
  • Site reference ID 203
    Moscow, Russian Federation
  • Site reference ID 204
    Moscow, Russian Federation
  • Site reference ID 205
    Saint Petersburg, Russian Federation
  • Site reference ID 305
    Ivano-Frankivs'k, Ukraine
  • Site reefrence ID 303
    Kyiv, Ukraine
  • Site reference ID 301
    Kyiv, Ukraine
  • Site reference ID 302
    Kyiv, Ukraine
  • SIte reference ID 304
    Kyiv, Ukraine
09

References and documents

Publications

  • Donnez J, Taylor HS, Taylor RN, Akin MD, Tatarchuk TF, Wilk K, Gotteland JP, Lecomte V, Bestel E. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial. Fertil Steril. 2020 Jul;114(1):44-55. doi: 10.1016/j.fertnstert.2020.02.114. Epub 2020 Jun 4. PubMed 32505383 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2016 to primary completion in Apr 2018, 21 months.

Results were first posted in Jul 2022, 4 years 3 months after primary completion. A results delay was requested in May 2019.

Of 44 phase 2 interventional studies under Endometriosis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 37. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2016
First posted
May 19, 2016
StartActual
Jul 2016
Primary completionActual
Apr 2018
CompletionActual
Jul 1, 2019
Results delay requested
May 21, 2019
Results first posted
Jul 21, 2022
Last update
Jul 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02778399
Lead sponsor
ObsEva SA
Responsible party
Sponsor
First posted
May 19, 2016
Start date
Jul 2016
Primary completion
Apr 2018
Completion
Jul 1, 2019
Results posted
Jul 21, 2022
Last update
Jul 21, 2022

Study contacts

ObsEva SA
study director · Geneva

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linzagolix

Start the discussion